Table 2.
Factors associated with fertility-sparing treatment outcomes.
| Variables | 16-week CR rate | P value | 32-week CR rate | P value | Progression | P value | Recurrence | P value | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Age≥30 | YES | 22.2% (12/54) | 0.150 | 53.7% (29/54) | 0.487 | 16.7% (9/54) | 0.411 | 18.0% (9/50) | 0.362 | |
| NO | 36.1% (13/36) | 61.1% (22/36) | 8.3% (3/36) | 8.6% (3/35) | ||||||
| BMI | <25 | 38.3% (18/47) | 0.066 | 72.3% (34/47) | 0.004 | 10.6% (5/47) | 0.143 | 8.7% (4/46) | 0.161 | |
| 25-30 | 16.1% (5/31) | 45.2% (14/31) | 22.6% (7/31) | 24.1% (7/29) | ||||||
| ≥30 | 16.7% (2/12) | 25.0% (3/12) | 0 | 10.0% (1/10) | ||||||
| IR | YES | 16.7% (6/36) | 0.055 | 38.9% (14/36) | 0.005 | 16.7% (6/36) | 0.532 | 12.5% (4/32) | 0.991 | |
| NO | 35.2% (19/54) | 68.5% (37/54) | 11.1% (6/54) | 15.1% (8/53) | ||||||
| MetS | YES | 23.8% (5/21) | 0.643 | 42.9% (9/21) | 0.145 | 19.0% (4/21) | 0.608 | 21.1% (4/19) | 0.541 | |
| NO | 29.0% (20/69) | 60.9% (42/69) | 11.6% (8/69) | 12.1% (8/66) | ||||||
| PCOS | YES | 33.3% (6/18) | 0.556 | 50.0% (9/18) | 0.523 | 5.6% (1/18) | 0.485 | 22.2% (4/18) | 0.465 | |
| NO | 26.4% (19/72) | 58.3 (42/72) | 15.3% (11/72) | 11.9% (8/67) | ||||||
| Hyperlipidemia | YES | 28.6% (16/56) | 0.829 | 57.1% (32/56) | 0.907 | 14.3% (8/56) | 0.983 | 15.1% (8/53) | 0.991 | |
| NO | 26.5% (9/34) | 55.9% (19/34) | 11.8% (4/34) | 12.5% (4/32) | ||||||
| Therapy | MA | 21.0% (13/62) | 0.073 | 43.5% (27/62) | <0.001 | 12.9% (8/62) | 0.011 | 8.6% (5/58) | 0.005 | |
| MPA | 0 | 50.0% (1/2) | 50.0% (1/2) | 0 | ||||||
| LNG-IUS | 33.3% (1/3) | 66.7% (1/3) | 66.7% (2/3) | 100.0% (2/2) | ||||||
| MA+LNG-IUS | 25.0% (1/4) | 50.0% (2/4) | 25.0% (1/4) | 50.0% (2/4) | ||||||
| GnRH-a+Letrozole | 52.6% (10/19) | 100.0% (19/19) | 0 | 15.8% (3/19) | ||||||
| Molecular classification | POLE | 0 | 0.173 | 50.0% (3/6) | 0.881 | 50.0% (3/6) | 0.013 | 0 | 0.037 | |
| MSI-H | 0 | 60.0% (3/5) | 40.0% (2/5) | 60.0% (3/5) | ||||||
| TP53 wt | 32.1% (25/78) | 57.7% (45/78) | 9.0% (7/78) | 12.0% (9/75) | ||||||
| TP53 abn | 0 | 0 | 0 | |||||||
| LP/P somatic mutant | YES | 23.7% (18/76) | 0.090 | 52.6% (40/76) | 0.072 | 15.8% (12/76) | 0.242 | 14.1% (10/71) | 1.000 | |
| NO | 50.0% (7/14) | 78.6% (11/14) | 0 | 14.3% (2/14) | ||||||
| PTEN | YES | 16.4% (9/55) | 0.002 | 49.1% (27/55) | 0.069 | 16.4% (9/55) | 0.458 | 11.5% (6/52) | 0.591 | |
| NO | 45.7% (16/35) | 68.6% (24/35) | 8.6% (3/35) | 18.2% (6/33) | ||||||
| PIK3CA | YES | 22.9% (8/35) | 0.406 | 48.6% (17/35) | 0.216 | 17.1% (6/35) | 0.596 | 12.1% (4/33) | 0.919 | |
| NO | 30.9% (17/55) | 61.8% (34/55) | 10.9% (6/55) | 15.4% (8/52) | ||||||
| KRAS | YES | 21.4% (3/14) | 0.801 | 35.7% (5/14) | 0.085 | 42.9% (6/14) | 0.002 | 16.7% (2/12) | 1.000 | |
| NO | 28.9% (22/76) | 60.5% (46/76) | 7.9% (6/76) | 13.7% (10/73) | ||||||
| MMR-related | YES | 0 | 0.271 | 66.7% (4/6) | 0.932 | 50.0% (3/6) | 0.029 | 20.0% (1/5) | 0.542 | |
| NO | 29.8% (25/84) | 56.0% (47/84) | 10.7% (9/84) | 13.8% (11/80) | ||||||
| TP53 | YES | 0 | 1.000 | 50.0% (1/2) | 1.000 | 50.0% (1/2) | 0.250 | 100.0% (1/1) | 0.141 | |
| NO | 28.4% (25/88) | 56.8% (50/88) | 12.5% (11/88) | 13.1% (11/84) | ||||||
| Maintenance Therapy | Dydrogesterone | – | – | – | 20.0% (1/5) | 0.002 | ||||
| LNG-IUS | 27.8% (5/18) | |||||||||
| Diane-35 + metformin | 6.7% (4/60) | |||||||||
| Diane-35 + metformin + LNG-IUS | 100.0% (1/1) | |||||||||
| none | 100.0% (1/1) | |||||||||
BMI, body mass index; IR, insulin resistance; MetS, metabolic syndrome; PCOS, polycystic ovary syndrome; MA, megestrol acetate; MPA, medroxyprogesterone acetate; LNG-IUS, levonorgestrel intrauterine system; GnRH-a, Gonadotropin-releasing hormone analogues; LP, likely pathogenic; P, pathogenic; MMR, mismatch repair.
Bold values means the P-value < 0.05, there is a statistical difference.